Efficacy and Safety of G-CSF in Patients With Severe Alcoholic Hepatitis With Null or Partial Response to Steroid

Alcoholic Hepatitis Clinical Trial

— GraCiAH  

Official title:

Efficacy and Safety of Granulocyte-colony Stimulating Factor in Patients With Severe Alcoholic Hepatitis With Null or Partial Response to Steroid: A Randomized, Double-blind, Placebo-controlled, Nationwide Multi-center Study

Clinical Trial Details — Status: Terminated

Administrative data

• NCT number: NCT02442180
• Other study ID #: 2014-6
• Status: Terminated
• Phase: Phase 3
• Start date: July 2015
• Est. completion date: July 2022

Study information

• Verified date: August 2022
• Source: Chuncheon Sacred Heart Hospital
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Steroid is the treatment of choice in patients with severe alcoholic hepatitis. However, null- or partial responder of steroid treatment is recommended to consider liver transplantation. The yearly demand for liver transplants far exceeds the supply of available organs and alcoholic liver disease has been a controversial indication for transplantation. Granulocyte-Colony Stimulating Factor (G-CSF) has been reported to have effect of proliferation of hepatic progenitors in alcoholic steatohepatitis. The aim of this study is to investigate the efficacy of G-CSF in patients with severe alcoholic hepatitis with null or partial response to steroid.

Description:

Severe alcoholic hepatitis is defined as alcoholic hepatitis patients having discriminant function (DF) score over 32 or accompanying hepatic encephalopathy. These patients have shown poor prognosis of 28 day mortality as 30 to 50% without treatment. Steroid (prednisolone 40mg/day for 28 days) is the treatment of choice in patients with severe alcoholic hepatitis. Alcoholic hepatitis with modified DF score greater than or equal to 32 or model for end-stage liver disease (MELD) score over 21 or with hepatic encephalopathy are indications. However, null- or partial responder of steroid treatment is recommended to consider liver transplantation. The yearly demand for liver transplants far exceeds the supply of available organs and alcoholic liver disease has been a controversial indication for transplantation. Even in the responders of steroid treatment, the mortality is still 20% (from 40% without treatment to 20% with steroid treatment). There is a need for development of new treatment for this catastrophic disease. Granulocyte-Colony Stimulating Factor (G-CSF) has been reported to have effect of proliferation of hepatic progenitors in alcoholic steatohepatitis. The aim of this study is to investigate the efficacy of G-CSF in patients with severe alcoholic hepatitis with null or partial response to steroid.

Recruitment information / eligibility

• Status: Terminated
• Enrollment: 64
• Est. completion date: July 2022
• Est. primary completion date: July 2022
• Accepts healthy volunteers: No
• Gender: All
• Age group: 21 Years to 79 Years

Eligibility

Inclusion Criteria: Patients with

• Clinical significant alcohol intake history (men over 50g within 3 months, women over 40g within 3 months)
• modified DF score greater than or equal to 32
• Transjugular liver biopsy shows typical feature of alcoholic hepatitis or meet the clinical diagnosis (total serum bilirubin level over 5 mg/dL, aspartate aminotransferase/alanine aminotransferase ratio >2, aspartate aminotransferase < 300 IU/L)
• Included patients should meet the all above criteria and Lille score > 0.16 at the day 7 of prednisolone 40mg (or 32 mg of methylprednisolone) daily treatment. Exclusion Criteria: Patients with
• hepatitis B surface antigen (HBsAg), anti-hepatitis C virus (anti-HCV), or anti-human immunodeficiency virus (HIV) (+)
• Malignancy including hepatocellular carcinoma
• Portal vein thrombosis, hemochromatosis, autoimmune hepatitis, Wilson's disease, alpha-1-antitrypsin deficiency
• Pregnancy, breast feeding, or who refuses contraception, or who cannot do contraception
• History of adverse event including allergic response, hypersensitivity to G-CSF
• Hypovolemic shock due to gastrointestinal hemorrhage or who need packed red blood cell (RBC) transfusion more than 3 units or increased modified discriminant factor (DF) score greater or equal to 32 from below 32 due to gastrointestinal hemorrhage
• Sepsis or uncontrolled acute infection
• Hepatic encephalopathy grade 3-4
• History of steroid or pentoxifylline treatment within 3 months
• Myeloblast on peripheral blood smear test
• Critical comorbidities (type I hepatorenal syndrome, serum creatinine >2.5mg/dL, heart failure, pulmonary disease, psychiatric disease, acute pancreatitis etc.)
• Who refuses to participate in clinical trial

Related Conditions & MeSH terms

• Alcoholic Hepatitis
• Hepatitis
• Hepatitis A
• Hepatitis, Alcoholic

Intervention

Drug:
• G-CSF (Filgrastim injection)
G-CSF (Filgrastim injection) 5ug/kg subcutaneous injection daily for 5 days and every 3 days (total 12 doses)
• steroid
oral prednisolone 40mg qd or iv methylprednisolone 32 mg if oral medication is not tolerable
• placebo
equivalent to G-CSF doses

Locations

Country	Name	City	State
Korea, Republic of	Chuncheon Sacred Heart hospital	Chuncheon

Sponsors (1)

Lead Sponsor	Collaborator
Chuncheon Sacred Heart Hospital

Country where clinical trial is conducted

Korea, Republic of, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	2-month survival rate of null responder to steroid treatment and 6-month survival rate of partial responder to steroid treatment	Survival status can be determined by the occurrence of mortality regardless of any cause of death.	After 2 months of G-CSF or placebo treatment in patients with null responder to steroid treatment and after 6 months of G-CSF+steroid or only steroid treatment in patients with partial responder to steroid treatment
Secondary	Hepatic function improvement as assessed by the Child-Pugh score	Hepatic function is defined as the Child-Pugh score.	day 0,1,3,7,9,11,14,17,20,23,26,29,32,35,60,90,120,150,180
Secondary	Hepatic function improvement as assessed by the MELD score	Hepatic function is defined as the MELD score.	day 0,1,3,7,9,11,14,17,20,23,26,29,32,35,60,90,120,150,180
Secondary	Hepatic function improvement as assessed by the Chronic Liver Failure (CLIF)-Sequential Organ Failure Assessment (SOFA) score	Hepatic function is defined as the CLIF-SOFA score.	day 0,1,3,7,9,11,14,17,20,23,26,29,32,35,60,90,120,150,180
Secondary	Hepatic function improvement as assessed by the Fraction of Cluster of differentiation (CD34)+ cell in peripheral blood	Hepatic function is defined as the CD34+ cell count percentage in circulating blood.	day0,7,35
Secondary	Hepatic function improvement as assessed by the Alcoholic Hepatitis Histology score	Hepatic function is defined as histological scoring system of alcoholic hepatitis (AHHS).	day0,35